跳到正文
原文
Nature Medicine· Florence Magrangeas·· 17 天前AI 评分27

Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy

Publisher Correction: Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy

AI 导读

Nature Medicine 发表了对新诊断多发性骨髓瘤采用四联疗法治疗后最小残留疾病分子预测因子的修正文章。原文已更正并发布在 HTML 和 PDF 版本中。

正文

Correction to: Nature Medicine https://doi.org/10.1038/s41591-026-04692-0, published online 19 October 2026.

In the version of this article initially published, text in the seventh and eighth sentences of the abstract was incomplete and is now amended in the HTML and PDF versions of the article.

Author information

Author notes

  1. These authors jointly supervised this work: Stéphane Minvielle, Eric Letouzé.

Authors and Affiliations

  1. Nantes Université, INSERM, CNRS, Université d’Angers, CRCI2NA, Nantes, France

    Florence Magrangeas, Mia Cherkaoui, Victor Bessonneau-Gaborit, Jennifer Derrien, Céline Chevalier, Catherine Guérin-Charbonnel, Philippe Moreau, Cyrille Touzeau, Stéphane Minvielle & Eric Letouzé

  2. Centre Hospitalier Universitaire de Nantes, Université de Nantes, Nantes, France

    Florence Magrangeas, Céline Chevalier, Stéphane Minvielle & Eric Letouzé

  3. Institut de Cancérologie de l’Ouest, Nantes, France

    Catherine Guérin-Charbonnel

  4. Myeloma Division, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA

    Benjamin Diamond & Ola Landgren

  5. Department of Data Science, Dana Farber Cancer Institute, Boston, MA, USA

    Mehmet Kemal Samur

  6. Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA

    Mehmet Kemal Samur

  7. Service d’Hématologie, Hôpital Haut Lévêque, Centre Hospitalier Universitaire de Bordeaux, Pessac, France

    Cyrille Hulin

  8. Service d’Hématologie, Centre Hospitalier Universitaire de Dijon, Dijon, France

    Denis Caillot

  9. Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d’Hematologie, Pierre-Benite, Université Claude Bernard Lyon 1, Lyon, France

    Lionel Karlin

  10. Immuno-hématologie, Hôpital Saint Louis, APHP, Université Paris Cité, Paris, France

    Bertrand Arnulf

  11. Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA

    Nikhil C. Munshi

  12. VA Boston Healthcare System, Boston, MA, USA

    Nikhil C. Munshi

  13. Cancer Research Center of Toulouse, INSERM, CNRS, Université Toulouse III-Paul Sabatier, Toulouse, France

    Hervé Avet-Loiseau, Ludovic Martinet & Jill Corre

  14. Institut Universitaire du Cancer, Centre Hospitalier Universitaire de Toulouse, Toulouse, France

    Hervé Avet-Loiseau, Ludovic Martinet & Jill Corre

  15. Université de Toulouse, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse–Oncopole, Service d’Hématologie, Toulouse, France

    Aurore Perrot

  16. Service d’Hématologie, Centre Hospitalier Universitaire de Nantes, Nantes, France

    Philippe Moreau & Cyrille Touzeau

Authors

  1. Florence Magrangeas
  2. Mia Cherkaoui
  3. Victor Bessonneau-Gaborit
  4. Jennifer Derrien
  5. Céline Chevalier
  6. Catherine Guérin-Charbonnel
  7. Benjamin Diamond
  8. Mehmet Kemal Samur
  9. Cyrille Hulin
  10. Denis Caillot
  11. Lionel Karlin
  12. Bertrand Arnulf
  13. Ola Landgren
  14. Nikhil C. Munshi
  15. Hervé Avet-Loiseau
  16. Ludovic Martinet
  17. Jill Corre
  18. Aurore Perrot
  19. Philippe Moreau
  20. Cyrille Touzeau
  21. Stéphane Minvielle
  22. Eric Letouzé

Consortia

Intergroupe Francophone du Myélome (IFM)

  • Cyrille Hulin
  • , Denis Caillot
  • , Lionel Karlin
  • , Bertrand Arnulf
  • , Hervé Avet-Loiseau
  • , Jill Corre
  • , Aurore Perrot
  • , Philippe Moreau
  • , Cyrille Touzeau
  •  & Stéphane Minvielle

Corresponding authors

Correspondence to Stéphane Minvielle or Eric Letouzé.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Magrangeas, F., Cherkaoui, M., Bessonneau-Gaborit, V. et al. Publisher Correction: Molecular predictors of minimal residual disease in newly diagnosed multiple myeloma treated with quadruplet therapy. Nat Med (2026). https://doi.org/10.1038/s41591-026-04792-x

Download citation

  • Published: 03 November 2026

  • Version of record: 03 November 2026

  • DOI: https://doi.org/10.1038/s41591-026-04792-x

来源:Nature Medicine · nature.com